<DOC>
	<DOC>NCT02938078</DOC>
	<brief_summary>The primary study objectives are: to evaluate (1) the change in ocular discomfort at 30 days and (2) the change in signs and symptoms of ocular surface disease in demodex-positive subjects beginning the use of Avenova.</brief_summary>
	<brief_title>Ocular Comfort and Inflammation in Lid Hygiene Therapy</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Blepharitis</mesh_term>
	<criteria>Subject signed and dated a IRBapproved informed consent document Mild or greater Demodex (minimum 15 observable mites in six lashes) Score of 20 or more on the OSDI Questionnaire Score of 20 or more on the Eyelid Inflammation Questionnaire Currently enrolled in another prospective research study Unable to attend two followup visits over 30 days Current allergic conjunctivitis of the cornea, conjunctiva, or eyelid in either eye Prior ocular trauma where surgery was indicated Prior corneal transplant in either eye Any ocular surgery within the past six months Abnormal corneal scarring, erosions, or StevensJohnson syndrome Anticipation of ocular surgery within the next 30 days NonEnglish speaking Pregnant, nursing, or expect to become pregnant within the next 30 days Known sensitivity to chlorine or Avenova Moderate, or severe conjunctivochalasis Contact lenses within the last 30 days and unwilling to discontinue for 30 days Use of topical cyclosporine for less than 6 continuous months prior to baseline Procedure such as pulsed light or commercial lid massage in last 30 days Known history of autoimmune disease Punctal plugs placed within the last 30 days Use of Avenova or other lid cleansers within the last 30 days Changes in systemic or ocular medications in the last 30 days Unwilling to commit to the same ocular and systemic medications for 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>